Compare NVGS & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVGS | MPLT |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | 133 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2013 | N/A |
| Metric | NVGS | MPLT |
|---|---|---|
| Price | $22.82 | $27.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $21.50 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 357.7K | 299.4K |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.50 | $12.24 |
| 52 Week High | $23.22 | $33.28 |
| Indicator | NVGS | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 69.68 | 50.35 |
| Support Level | $17.38 | $27.00 |
| Resistance Level | N/A | $32.68 |
| Average True Range (ATR) | 0.70 | 2.66 |
| MACD | 0.15 | -0.58 |
| Stochastic Oscillator | 87.58 | 15.67 |
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). The company plays a vital role in the globalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users, and commodity traders.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.